Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA)

International Journal of Antimicrobial Agents

Volumn 33, Issue 1, 2009, Pages 65-69

  Galani, Lambrini ^a   Pefanis, Angelos ^b   Sakka, Vissaria ^a   Iliopoulos, Dimitrios ^b   Donta, Ismini ^b   Triantafyllidi, Helen ^a   Skiadas, Ioannis ^a   Karayiannakos, Panayiotis ^b   Giamarellou, Helen ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Fluoroquinolones; MRSA; Rabbits; Resistance; Vancomycin

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; OXACILLIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RABBIT; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AORTIC VALVE; AZA COMPOUNDS; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; FEMALE; HEART VALVE DISEASES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 59349100307     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.021     Document Type: Article

References (31)

1. Moreillon P., and Que Y. Infective endocarditis. Lancet 363 (2004) 139-149
2. Bouza E., Menasalvas A., Munoz P., Vasallo F.J., del Mar Moreno M., and García Fernández M.A. Infective endocarditis: a prospective study at the end of the twentieth century-new predisposing conditions, new etiologic agents, and still a high mortality. Medicine (Baltimore) 80 (2001) 298-307
3. Fowler Jr. V.G., Miro J.M., Hoen B., Cabel C.H., Abrutyn E., Rubinstein E., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021
4. Fowler Jr. V.G., Kong L.K., Corey G.R., Gottlieb G.S., McClelland R.S., Sexton D.J., et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 179 (1999) 1157-1161
5. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115 (1991) 674-680
6. Lister P.D. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 32 Suppl. 1 (2001) S33-S38
7. Jones M.E., Visser M.R., Klootwijk M., Heisig P., Verhoef J., and Schmitz F.J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 43 (1999) 421-423
8. Hardy D., Amsterdam D., Mandell L.A., and Rotstein C. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob Agents Chemother 44 (2000) 802-805
9. Blondeau J.M. A review of the comparative in vitro activities of 12 antimicrobial agents, with focus on five new 'respiratory quinolones'. J Antimicrob Chemother 43 Suppl. B (1999) 1-11
10. Sakka V., Galani L., Pefanis A., Iliopoulos D., Athanasopoulos G., Donta I., et al. Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. J Antimicrob Chemother 56 (2005) 1160-1162
11. Entenza J.M., Que Y.A., Vouillamoz J., Glauser M.P., and Moreillon P. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Antimicrob Agents Chemother 45 (2001) 3076-3083
12. Allen G.P., Kaatz G.W., and Rybak M.J. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents 24 (2004) 150-160
13. Stass H., and Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 43 Suppl. B (1999) 83-90
14. Louie L., Matsumura S.O., Choi E., Louie M., and Simor A.E. Evaluation of three rapid methods for detection of methicillin resistance in Staphylococcus aureus. J Clin Microbiol 38 (2000) 2170-2173
15. Discotto L.F., Lawrence L.E., Denbleyker K.L., and Barrett J.F. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob Agents Chemother 45 (2001) 3273-3275
16. Linde H.J., Schmidt M., Fuchs E., Reischl U., Niller H.H., and Lehn N. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother 45 (2001) 1553-1557
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17 (2007), CLSI, Wayne, PA
18. Perlman B.B., and Freedman L.R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med 44 (1971) 206-213
19. Siaperas P., Pefanis A., Iliopoulos D., Katsarolis I., Kyroudi-Voulgari A., Donta I., et al. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone. Antimicrob Agents Chemother 45 (2001) 3531-3537
20. Fox P.M., Lampen R.J., Stumpf K.S., Gordon L., Archer G.L., and Clim M.W. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and β-lactam antibiotics. Antimicrob Agents Chemother 50 (2006) 2951-2956
21. Skiadas I., Pefanis A., Papalois A., Kyroudi A., Triantafyllidi H., Tsaganos T., et al. Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 2848-2854
22. Perdikaris G., Giamarellou H., Pefanis A., Donta I., and Karayiannakos P. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob Agents Chemother 39 (1995) 2289-2294
23. Wise R., Andrews J.M., Marshall G., Dvorchik B., and Marshall G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 43 (1999) 1508-1510
24. Burkhardt O., Borner K., Stass H., Beyer G., Allewelt M., Nord C.E., et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva, and faeces. Scand J Infect Dis 34 (2002) 898-903
25. Andes D.R., and Graig W.A. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 27 (1998) 47-50
26. Lacy M.K., Lu W., Xu X., Tessier P.R., Nicolau D.P., Quintiliani R., et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43 (1999) 672-677
27. Firsov A.A., Vostrov S.N., Lubenko I.Y., Drlica K., Portnoy Y.A., and Zinner S.H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47 (2003) 1604-1613
28. Dalhoff A., Heidtmann M., Schubert S., and Ullmann U. Pharmacodynamics of moxifloxacin in fibrin clots. Clin Microbiol Infect 8 Suppl. 1 (2002) 316
29. Park H.S., Yoon Y.M., Jung S.J., Kim C.M., Kim J.M., and Kwak J.H. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. J Antimicrob Chemother 60 (2007) 568-574
30. Berrington A.W., Koerner R.J., Perry J.D., Bain H.H., and Gould F.K. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int J Med Microbiol 291 (2001) 237-239
31. Parish L.C., Routh H.B., Miskin B., Fidelholtz J., Werschler P., Heyd A., et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 54 (2000) 497-503